3.77
-0.19(-4.80%)
Currency In USD
| Previous Close | 3.96 |
| Open | 3.86 |
| Day High | 3.98 |
| Day Low | 3.64 |
| 52-Week High | 4.54 |
| 52-Week Low | 0.91 |
| Volume | 1.9M |
| Average Volume | 2.39M |
| Market Cap | 339M |
| PE | -1.33 |
| EPS | -2.84 |
| Moving Average 50 Days | 3.07 |
| Moving Average 200 Days | 2.1 |
| Change | -0.19 |
If you invested $1000 in Editas Medicine, Inc. (EDIT) since IPO date, it would be worth $207.14 as of October 19, 2025 at a share price of $3.77. Whereas If you bought $1000 worth of Editas Medicine, Inc. (EDIT) shares 5 years ago, it would be worth $112.67 as of October 19, 2025 at a share price of $3.77.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
GlobeNewswire Inc.
Oct 09, 2025 3:01 PM GMT
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse modelsCAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing com
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
GlobeNewswire Inc.
Oct 06, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming Eu
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
GlobeNewswire Inc.
Sep 02, 2025 11:00 AM GMT
EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsored webinar on